Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma’s ADC pipeline

Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.